Telemedicine leader Teladoc Health is struggling with declining revenue as demand wanes post-pandemic. Efforts to turn things around have been unsuccessful, leading investors to consider other healthcare stocks like Pfizer, which saw significant success with Covid vaccines and antiviral treatments. Pfizer’s clear path to recovery makes it a better investment option.

Pfizer’s revenue and earnings surged during the pandemic but have since declined. The company’s strategic acquisitions have expanded its pipeline, with new products expected to stabilize sales and earnings growth. Pfizer’s focus on oncology and other therapies, along with over 100 programs in clinical trials, positions it for a rebound unlike Teladoc.

Despite Teladoc’s ecosystem and international expansion efforts, the company struggles to establish itself in virtual therapy, facing fierce competition and financial losses. In contrast, Pfizer’s market position and strategic moves make it a more promising investment. Investors should consider the long-term potential of Pfizer over Teladoc.

The Motley Fool Stock Advisor team identified 10 top stocks for investors to buy now, excluding Pfizer. This list has historically produced substantial returns, outperforming the S&P 500. With Pfizer’s clear path to growth and stability, it remains a strong choice for investors seeking reliable returns in the healthcare sector.

Read more at Yahoo Finance: Forget Teladoc and Buy This Healthcare Stock Instead